IGC Pharma/$IGC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About IGC Pharma
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
Ticker
$IGC
Sector
Primary listing
AMEX
Employees
70
Headquarters
Website
IGC Pharma Metrics
BasicAdvanced
$25m
-
-$0.08
0.45
-
Price and volume
Market cap
$25m
Beta
0.45
52-week high
$0.50
52-week low
$0.24
Average daily volume
406k
Financial strength
Current ratio
1.324
Quick ratio
0.787
Long term debt to equity
1.693
Total debt to equity
1.804
Profitability
EBITDA (TTM)
-7.524
Gross margin (TTM)
46.20%
Net profit margin (TTM)
-582.82%
Operating margin (TTM)
-731.92%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-50.31%
Return on equity (TTM)
-83.34%
Valuation
Price to revenue (TTM)
18.617
Price to book
2.83
Price to tangible book (TTM)
7.13
Price to free cash flow (TTM)
-3.288
Free cash flow yield (TTM)
-30.41%
Free cash flow per share (TTM)
-0.076
Growth
Revenue change (TTM)
-6.51%
Earnings per share change (TTM)
-57.08%
3-year revenue growth (CAGR)
17.72%
10-year revenue growth (CAGR)
-18.65%
3-year earnings per share growth (CAGR)
-34.20%
10-year earnings per share growth (CAGR)
-9.84%
IGC Pharma News
AllArticlesVideos
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign
Accesswire·3 days ago
IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow
Accesswire·3 weeks ago
IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company
Accesswire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.